Anaphylaxis is a serious allergic reaction that affects multiple body systems and can cause death. It is caused by an immune system response to an allergen that results in the release of chemicals like histamine from mast cells that cause symptoms. Symptoms can include skin issues, respiratory distress, gastrointestinal issues, and cardiovascular problems. Treatment involves epinephrine injection, antihistamines, corticosteroids, monitoring vitals, and emergency transport if needed. Prevention focuses on having emergency medications available and management plans for high risk individuals.
an extreme, often life-threatening allergic reaction to an antigen to which the body has become hypersensitive.,an extreme, often life-threatening allergic reaction to an antigen to which the body has become hypersensitive.
an extreme, often life-threatening allergic reaction to an antigen to which the body has become hypersensitive.,an extreme, often life-threatening allergic reaction to an antigen to which the body has become hypersensitive.
Anaphylaxis is a emergency for the dental office and can potentially lead to an anaphylactic shock.
Methods of management are mentioned in the presentation.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Anaphylaxis is a emergency for the dental office and can potentially lead to an anaphylactic shock.
Methods of management are mentioned in the presentation.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
2. Anaphylaxis
Anaphylaxis is a serious allergic reaction that is rapid in onset
and manifests as under and may cause death.
❖ Cutaneous : urticaria, angioedema, flushing
❖ Respiratory : bronchospasm, laryngeal edema
❖ Cardiovascular : hypotension, dysrhythmias,
myocardial ischemia
❖ Gastrointestinal: nausea, colicky abdominal pain,
vomiting, diarrhea
Mediated by biological substances
released from mast cells and basophils.
2
3. Anaphylaxis - Etymology
❖ Ancient Greek
➢ aná - intensifier
➢ phúlaxis - protection (by antibodies)
Become extremely
sensitive to harmless
allergens to cause
anaphylaxis
Antibodies that normally
protect our body from
microbes
3
Multi-systemic symptoms of Anaphylaxis
Allergen
4.
5. Pathophysiology of Anaphylaxis
B Cell
Immediate hypersensitivity
reaction (minutes after
repeat exposure to
allergen)
Allergen(e.g. pollen)
Allergen
Exposure
IgE-secreting
B cell
IgE
B cell
Dendritic Cell
Production of IgE
TH2 Cell
Naive T Cell
Dendritic cell
IgE
Cytokines
Activation
of mast cell;
release of
mediators
Binding of IgE
to FCƐRI on
mast cells
Late phase reaction (2-
24 hours after repeat
exposure to allergen)
Vasoactive amines, lipid mediators
Binding of IgE
to FCƐRI on
mast cells
Mediators
B Cell
Activation of TH2
cells and IgE class
switching in B cell
8. Exercise induced anaphylaxis
(EIAn)
o Symptoms occur after physical activity.
o In one third of cases food, drugs (especially NSAID) &
change in temp, can be identified.
o When symptoms develop after food ingestion, the
condition is referred as food-dependent exercise induced
anaphylaxis (FDEIAn).
o Fasting before exercise is of utmost importance when no
precise food has been correlated with the clinical
manifestations.
9. Risk Factors for Anaphylaxis
❖ Concomitant Diseases
➢ Asthma, Allergic rhinitis and Eczema
➢ Mastocytosis
➢ Depression, cognitive dysfunction, substance misuse
❖ Drugs
➢ β-Adrenergic blockers; Angiotensin-converting enzyme (ACE) inhibitors
➢ Sedatives, antidepressants, narcotics, recreational drugs
➢ Alcohol may lower patient’s ability to recognize triggers and symptoms
9
10. ❖ Cofactors that Amplify Anaphylaxis
➢ Exercise: may be food dependent or food independent;
➢ NSAIDs
➢ Acute infection
➢ Emotional stress
➢ Disruption of routine—for example, travel, jet lag
➢ Premenstrual status in women and girls
11. Anaphylactic preparedness
Algorithm Management of Anaphylaxis
1. Manpower(trained in prompt assessment and
management of anaphylaxis)
2. Equipments:- (oxygen, suction, larygoscope,
ambu bag, mask, endotracheal tube, IV canulas)
3. Drugs
4. Fluids
5. Communication
12. Initial management
Yes
• Assess airway, breathing,
circulation, mentation
• Inject epinephrine(IM)*
• Supine position
• IV access, oxygen, monitoring
No
Initial assessment supports
potential anaphylaxis?
Consider other diagnosis
*0.01ml/kg Epinephrine1:1000[IM]
13. Good clinical
response?
Yes
No
Recumbent position with elevation
lower extremity • Establish airway,
O2 • Repeat epinephrine injection if
indicated
• IV fluids1 if hypotensive
Consider inhaled bronchodilators2 if
wheezing
• H1 and H2 antihistamines3
• Corticosteroids4
• Observation
• Autoinjectible
epinephrine
1NS or RL-30 mL/kg in 1st hr
2 Nebulised Albuterol- (0.83 mg/mL [3 mL]) via mask with O2
3cetrizine-0.25 mg/kg up to 10 mg PO, Ranitidine-1 mg/kg up to 50 mg IV
4methylprednisolone- 1-2 mg/kg up to 125 mg IV
14. Poor clinical
response
• Epinephrine intravenous
infusion*
• Other intravenous
vasopressors
• Consider glucagon
Cardiopulmonary arrest during
anaphylaxis:
• CPR and ACLS measures • Consider:
High-dose epinephrine
Rapid volume expansion
Atropine for asystole or pulseless
electrical activity • Transport to
ICU
*0.01 mL/kg/dose of 1:10,000 IV
15. POSTEMERGENCY MANAGEMENT
Antihistamine-Cetirizine (5-10 mg qd) or
loratadine (5-10 mg qd) for 3 days
Corticosteroids(Optional): Oral prednisone (1 mg/kg up to 75
mg) daily for 3 days
Preventive treatment
• Prescription for epinephrine
autoinjector(Epipen) and antihistamine
• Written plan outlining patient emergency
management
• Follow-up evaluation to determine/confirm